Juling Wang, Shengming Ruan, Tengfei Yu, Xiaoxiao Meng, Juan Ran, Chaozhu Cen, Cuifang Kong, Xunxia Bao, Zhenzhen Li, Yi Wang, Mengfei Ren, Pin Guo, Yanbin Teng, Daoxiang Zhang
Glioblastoma multiforme (GBM) is the most common and aggressive primary malignant human brain tumor. Although comprehensive therapies, including chemotherapy and radiotherapy following surgery, have shown promise in prolonging survival, the prognosis for GBM patients remains poor, with an overall survival rate of only 14.6 months. Chemoresistance is a major obstacle to successful treatment and contributes to relapse and poor survival rates in glioma patients. Therefore, there is an urgent need for novel strategies to overcome chemoresistance and improve treatment outcomes for human glioma patients...
May 9, 2024: Cellular Signalling